DEVELOPMENT OF STANDARDIZATION APPROACHES FOR RECOMBINANT ENDOLYSIN LYSECD7-BASED PHARMACEUTICAL SUBSTANCE

DOI: https://doi.org/10.29296/25877313-2020-09-01
Issue: 
9
Year: 
2020

N.P. Antonova Post-graduate Student, Research Scientist, N.F. Gamaleya National Research Centre for Epidemiology and Microbiology, Ministry of Health of the Russian Federation; Lomonosov Moscow State University (Moscow) E-mail: northernnatalia@gmail.com D.V. Vasina Ph.D. (Biol.), Research Laboratory Assistant, N.F. Gamaleya National Research Centre for Epidemiology and Microbiology, Ministry of Health of the Russian Federation (Moscow) E-mail: d.v.vasina@gmail.com V.U. Balabanyan Dr.Sc. (Pharm.), Associate Professor, Lomonosov Moscow State University (Moscow) E-mail: bal.pharm@mail.ru V.A. Gushchin Ph.D. (Biol.), Senior Research Scientist, N.F. Gamaleya National Research Centre for Epidemiology and Microbiology, Ministry of Health of the Russian Federation; Lomonosov Moscow State University (Moscow) E-mail: wowaniada@gmail.com

Relevance. Lytic bacteriophages endolysins represent one of the most promising classes of antibacterial agents in the post-antibiotic era. Since this class of antibacterials is quite new there is an urgent need for development of approaches to the endolysins pharmaceutical substances standardiza-tion. Objective of the study was to develop the approaches to the recombinant endolysin LysECD7 pharmaceutical substance standardization. Materials and methods. The identity and purity of the endolysin pharmaceutical substance was assessed by SDS-PAGE in 16% polyacrylamide gel. The specific antibacterial activity of the LysECD7 pharmaceutical substance was determined using a novel microbiological method counting the CFU reduction of the Acinetobacter baumannii Ts 50-16 test strain after the endolysin exposure. The sterility of the LysECD7 pharmaceutical substance was determined by the membrane filtration method. The bacterial endotoxins level was determined by a chromogenic endpoint test. The quantity of the protein in the pharmaceutical substance was determined by the colorimetric method with bicinchoninic acid. Results. During the work the approaches to the standardization of the endolysin LysECD7 pharmaceutical substance were developed including the basic quality attributes such as "Electrophoresis in polyacrylamide gel" and "Specific activity" to confirm the identity, "Sterility", "Bacterial endotoxins" and "Quantification". Conclusions. Approaches to the standardization of the LysECD7 endolysin pharmaceutical substance were developed including such quality attributes as "Identity", "Purity" and "Quantification", which allow to reach the stable efficiency and safety of the pharmaceutical substance aiming to develop in-novative effective antibacterial drugs.

Keywords: 
Endolysins
LysECD7
Gram-negative bacteria
pharmaceutical substance
standardization
quality control

References: 
  1. Oliveira H., São-José C., Azeredo J. Phage-derived peptidoglycan degrading enzymes: challenges and future prospects for in vivo therapy. Viruses. 2018; 10(6): 292.
  2. Schmelcher M., Donovan D.M., Loessner M.J. Bacteriophage endolysins as novel antimicrobials. Future Microbiol. 2012; 7(10): 1147–71.
  3. Nazarov P.A. Al'ternativy antibiotikam: liticheskie fermenty bakteriofagov i fagovaya terapiya. Vestnik RGMU. 2018; 1: 5–15.
  4. Antonova N.P., Balaban'yan V.Yu., Tkachuk A.P. Makarov V.V., Gushchin V.A. Fiziko-himicheskie svojstva i protivomikrobnaya aktivnost' rekombinantnogo fagolizina bak-teriofaga kpp10, dejstvuyushchego na Pseudomonas aeruginosa. Vestnik RGMU. 2018; 1: 22–9.
  5. Lood R., Winer B.Y., Pelzek A.J. et al. Novel phage Lysin capable of killing the multidrug-resistant gram-negative bacterium Acinetobacter baumannii in a mouse bacte-remia model. Antimicrob. Agents Chemother. 2015; 59(4): 1983–91.
  6. Larpin Y., Oechslin F., Moreillon P. et al. In vitro characterization of PlyE146, a novel phage lysin that targets Gram-negative bacteria. PLoS ONE. 2018; 13(2): e0192507.
  7. Antonova N.P., Vasina D.V., Lendel A.M. et al. Broad bactericidal activity of the Myoviridae bacteriophage lysins LysAm24, LysECD7, and LysSi3 against Gram-negative ESCAPE pathogens. Viruses. 2019; 11(3): e284.
  8. Gosudarstvennaya Farmakopeya Rossijskoj Federacii XIV izdaniya. M. 2018.
  9. Federal'nyj zakon ot 12.04.2010 №61-FZ «Ob obrashchenii lekarstvennyh sredstv».